![Emerging Drugs and Targets for Alzheimers Disease: Volume 2: Neuronal](https://d3525k1ryd2155.cloudfront.net/f/648/730/9781849730648.ME.0.m.jpg)
Stock Photo: Cover May Be Different
Emerging Drugs and Targets for Alzheimers Disease: Volume 2: Neuronal Plasticity Hardcover - 2010
by Ana Martinez,
- New
- Hardcover
- first
Description
New
NZ$112.47
NZ$16.54
Shipping to USA
Standard delivery: 7 to 12 days
More Shipping Options
Standard delivery: 7 to 12 days
Ships from DELHI BOOK STORE (India)
About DELHI BOOK STORE India
Biblio member since 2007
Our prime concern is to make books available with its extensive choices of titles on all subjects for medicine, engineers, technocrats, corporates, scientists, academics, students, scholars and many more at attractive price range.
Details
- Title Emerging Drugs and Targets for Alzheimer’s Disease: Volume 2: Neuronal Plasticity
- Author Ana Martinez,
- Binding Hardcover
- Edition 1 ST
- Condition New
- Pages 326
- Volumes 1
- Language ENG
- Publisher Royal Society of Chemistry, Cambridge, England
- Date 2010
- Features Bibliography, Index, Table of Contents
- Bookseller's Inventory # AME_9781849730648
- ISBN 9781849730648 / 1849730644
- Weight 1.36 lbs (0.62 kg)
- Dimensions 9.2 x 6.2 x 1 in (23.37 x 15.75 x 2.54 cm)
- Dewey Decimal Code 616.831
From the rear cover
Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.